Loading...
Market
What will be the outcome of the FDA AdComm meeting on Soleno's NDA for DCCR by December 27, 2024?
2
Soleno Therapeutics•FDA•New Drug Application•NDA•DCCR•Diazoxide Choline•PDUFA•Advisory Committee•AdComm•SpringWorks Therapeutics•Mirdametinib
Resolution / Starting Odds
Approval recommended • 25%
Approval not recommended • 25%
No consensus • 25%
Meeting postponed • 25%
FDA official announcement or press release
Story
FDA Accepts Soleno's NDA for DCCR with PDUFA 12/27/24 and Grants Priority Review to SpringWorks' Mirdametinib
Aug 28, 2024, 10:34 AM
Soleno Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for DCCR (Diazoxide Choline) extended-release tablets, designed to treat Prader-Willi Syndrome, for priority review. The Prescription Drug User Fee Act (PDUFA) date for this application is set for December 27, 2024. The FDA also plans to hold an Advisory Committee (AdComm) meeting regarding this application. In a separate development, the FDA has granted priority review to SpringWorks Therapeutics' NDA for Mirdametinib, intended for the treatment of adults and children with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN). SpringWorks Therapeutics' stock saw a pre-market increase of 2.1% following this announcement.
View original story
Similar markets
Approved • 25%
Not Approved • 25%
Conditional Approval • 25%
Approval Delayed • 25%
Approved • 25%
Approved with conditions • 25%
Rejected • 25%
Review extended • 25%
Approval • 25%
Conditional Approval • 25%
Rejection • 25%
Request for More Data • 25%
Increase >10% • 25%
Increase <=10% • 25%
Decrease <=10% • 25%
Decrease >10% • 25%
Yes • 50%
No • 50%
Significant Increase (>20%) • 25%
Moderate Increase (10-20%) • 25%
No Significant Change • 25%
Decrease • 25%
Approved • 25%
Approved with Conditions • 25%
Not Approved • 25%
Decision Delayed • 25%
Top-selling PWS treatment • 25%
Moderate market success • 25%
Limited market impact • 25%
Withdrawn from market • 25%
Launches new product • 25%
Announces partnership • 25%
Pursues merger/acquisition • 25%
No major move • 25%